Benchmark Reaffirms Buy Rating for Surgery Partners (NASDAQ:SGRY)

Surgery Partners (NASDAQ:SGRY – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Benchmark in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $50.00 target price on the stock. Benchmark’s price target would suggest a potential upside of 103.83% from the company’s current price. […]

Related Keywords

United States ,Canada ,Jason Eric Evans ,Zurcher Kantonalbank Zurich Cantonalbank ,Bradleyr Owens ,York Mellon Corp ,Raymond James Associates ,Cantor Fitzgerald ,Royal Bank ,Citigroup ,Surgery Partners Company Profile ,Surgery Partners Inc ,Barclays ,Redwood Investments ,Securities Exchange Commission ,Surgery Partners ,Get Free Report ,Partners Trading Down ,Eric Evans ,Exchange Commission ,New York Mellon Corp ,Kantonalbank Zurich Cantonalbank ,Inspire Advisors ,Surgery Partners Daily ,